Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer

PURPOSE: Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer (NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) contributes to radiation resistance, we undertook a phase II trial of the EGFR inhibitor erlotinib with whole-brain radiation t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Welsh, James W., Komaki, Ritsuko, Amini, Arya, Munsell, Mark F., Unger, Wyatt, Allen, Pamela K., Chang, Joe Y., Wefel, Jeffrey S., McGovern, Susan L., Garland, Linda L., Chen, Su S., Holt, Jamie, Liao, Zhongxing, Brown, Paul, Sulman, Erik, Heymach, John V., Kim, Edward S., Stea, Baldassarre
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2013
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3577951/
https://ncbi.nlm.nih.gov/pubmed/23341526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.1174
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge